Puma Biotechnology

306 articles with Puma Biotechnology

• Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)

  11/17/2020

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 10 abstracts that will be presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) from Dec 8-11, 2020

• Puma Biotechnology Reports Awards Under Nasdaq Listing Rule 5635(c)(4)

  11/6/2020

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 3, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 44,750 shares of Puma common stock to 5 new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on

• Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer

  11/5/2020

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor (EGFR) exon 18 mutations that has been previously treated with an EGFR targeted tyrosine kinase inhibitor (TKI).

• Puma Biotechnology Reports Third Quarter 2020 Financial Results

  11/5/2020

  Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2020.

• Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference

  11/3/2020

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:15 p.m. EST on Tuesday, November 10, at the Credit Suisse 29th Annual Healthcare Conference.

• NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers

  10/15/2020

  The National Comprehensive Cancer Network ® ( NCCN ® ) Oncology Research Program ( ORP ) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual

• Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer

  10/5/2020

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC) from the Phase III ExteNET trial were published in Clinical Breast Cancer.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Oct 02, 2020

  10/2/2020

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on October 1, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 12,375 shares of Puma common stock to 2 new non-executive employees.

• Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/8/2020

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:30 a.m. EDT on Tuesday, Sept. 15, at the H.C. Wainwright 22nd Annual Global Investment Conference.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Sep 03, 2020

  9/3/2020

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on September 2, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 66,688 shares of Puma common stock to 10 new non-executive employees.

• Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology

  8/19/2020

  - CONTROL Trial Investigates Anti-diarrheal Strategies Including Dose Escalation in Neratinib-treated Patients with Early Stage HER2-positive Breast Cancer - Dose Escalation Resulted in Reduced Rate, Severity and Duration of Grade ≥ 3 Diarrhea Compared to Phase III ExteNET Trial, Lower Diarrhea-related Discontinuations and Dose Reductions in Multiple CONTROL Cohorts LOS ANGELES--( BUSINESS WIRE )-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a b

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Aug 10, 2020

  8/10/2020

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on August 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 32,000 shares of Puma common stock to six new non-executive employees.

• Puma Biotechnology Reports Second Quarter 2020 Financial Results

  8/6/2020

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2020. Unless otherwise stated, all comparisons are for the second quarter of 2020 compared to the second quarter of 2019.

• Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers

  7/27/2020

  Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2 -Mutant, Metastatic Cervical Cancers Data published online in Gynecologic Oncology LOS ANGELES--( BUSINESS WIRE )-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that data from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the safety and efficacy of neratinib in HER2 -mutated

• Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results - July 23, 2020

  7/23/2020

  Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m.

• Acentrus Specialty Partners with Puma Biotechnology to Bring Nerlynx® (neratinib) to Health Systems and Hospitals in the Acentrus Network

  7/21/2020

  Acentrus Specialty™, a national network of health systems and hospitals committed to providing specialty pharmacy care for their patients, has finalized an agreement with Puma Biotechnology, Inc.

• Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer

  7/16/2020

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX® (neratinib) in Malaysia from the Drug Control Agency (DCA), under Malaysia’s Ministry of Health (MOH).

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - July 09, 2020

  7/9/2020

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on July 8, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 24,500 shares of Puma common stock to six new non-executive employees.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2020

  6/2/2020

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on June 1, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 98,494 shares of Puma common stock to 13 new non-executive employees.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 08, 2020

  5/8/2020

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on May 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 78,125 shares of Puma common stock to 12 new non-executive employees.